Methacrylic Acid

Methacrylic Acid

SCHEMBL974640

C=C(C)C(=O)O.C=C(C)C(=O)OCC

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.57
TSHR P16473 4/20 0.50
ALDH1A1 P00352 8/20 0.48
LMNA P02545 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GLO1 Q04760 1/20 0.45
MAPT P10636 2/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
EGLN1 Q9GZT9 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
CYP2D6 P10635 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX15 P16050 1/20 0.39
SOAT1 P35610 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methacrylic Acid SCHEMBL9472725 1.00 THRB (0.57) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL2802555 1.00 THRB (0.57) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL28847790 0.98 THRB (0.55) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL29065401 0.98 THRB (0.55) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL29114833 0.98 THRB (0.55) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL25171144 0.96 THRB (0.53) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL17164482 0.96 THRB (0.53) THRBTSHRALDH1A1LMNAHSD17B10
Oxalic Acid SCHEMBL7517411 0.95 THRB (0.57) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL17360628 0.94 THRB (0.52) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL22164150 0.94 THRB (0.52) THRBTSHRALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676438-A1 FILM DELIVERY SYSTEM WITH PERFORATIONS LTS Lohmann Therapie-Systeme AG (DE) 2026-01-14 EP claimed
WO-2024218397-A1 PHAGE COMPOSITION Université Libre de Bruxelles (BE) 2024-10-24 WO claimed
EP-4450066-A1 PHAGE COMPOSITION Université Libre de Bruxelles (BE) 2024-10-23 EP claimed
WO-2024184460-A1 FILM DELIVERY SYSTEM WITH PERFORATIONS LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2024-09-12 WO claimed
CN-118291037-A Water-based super-hydrophobic coating and preparation method and application thereof 中国石油大学(华东) 2024-07-05 CN claimed
US-20240216299-A1 TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2024-07-04 US claimed
CN-118019524-A Dydrogesterone sustained release pharmaceutical composition 曼肯制药有限公司 2024-05-10 CN claimed
WO-2024079518-A1 MODIFIED RELEASE FORMULATION COMPRISING CAPSAICINOIDS AND A PROCESS NUTRIVENTIA LIMITED (IN) 2024-04-18 WO claimed
CN-117624953-A Coating for denitrification film, super-hydrophobic film containing coating and preparation method of super-hydrophobic film 中国海诚工程科技股份有限公司 2024-03-01 CN claimed
CN-117503982-A Gel dressing and preparation method and application thereof 中国科学院长春应用化学研究所 2024-02-06 CN claimed
WO-2006008524-A1 HOLOGRAPHIC SENSOR HAVING HETEROGENEOUS PROPERTIES CAMBRIDGE ENTERPRISE LIMITED (GB) 2006-01-26 WO claimed
WO-2005044240-A2 STABLE LANSOPRAZOLE FORMULATION DEXCEL, LTD. (IL) 2005-05-19 WO claimed
EP-1187599-A4 STABLE BENZIMIDAZOLE FORMULATION DEXCEL LTD (IL) 2004-05-19 EP claimed
EP-1187599-A1 STABLE BENZIMIDAZOLE FORMULATION Dexcel Ltd. (IL) 2002-03-20 EP claimed
WO-2001040370-A2 IONICALLY CROSSLINKED HYDROGELS WITH ADJUSTABLE GELATION TIME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2001-06-07 WO claimed
CN-1278733-A Viscous compositions containing carbon dioxide MEDICAL RES LAB INC (JP) 2001-01-03 CN claimed
WO-2000078284-A1 STABLE BENZIMIDAZOLE FORMULATION DEXCEL LTD. (IL) 2000-12-28 WO claimed
WO-2000055253-A1 IONOMER COMPOSITE COMPOSITIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2000-09-21 WO claimed
CN-1235824-A Process for producing enteric coated pancreatin granules IL YANG PHARM CO LTD (KR) 1999-11-24 CN claimed
US-4782100-A DENTURE LININGS TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1988-11-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216299-A1 TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE COMT, SLC6A3, SLC18A2 THRB 2087/4885TSHR 2150/4885ALDH1A1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.